NASDAQ · SHPH
Shuttle Pharmaceuticals Holdings, Inc.
$5.23-$0.01 (-0.19%)
Shuttle Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.22% below the high.
Loading market information…
NASDAQ · ISPC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
iSpecimen Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow iSpecimen Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $1.48M-50.44% vs estimate |
| Q3 2024 | Nov 7, 2024 | -$0.84+44.74% vs estimate | $2.66M-9.67% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.23-$0.01 (-0.19%)
Shuttle Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.22% below the high.
$3.03-$0.11 (-3.5%)
bioAffinity Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.25% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$0.19-$0.00 (-1.53%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.99% below the high.
$4.88+$0.14 (+2.95%)
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
$4.63+$0.81 (+21.05%)
Galmed Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.92% below the high.
$0.54-$0.03 (-5.08%)
Bluejay Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.1% below the high.
